Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.43 |
| ▸ | HEXA | P06865 | 1/20 | 0.38 |
| ▸ | HEXB | P07686 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 6/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847011 | 0.92 | MAP4K4 (0.41) | TLR8MAP4K4CHEK2DHFR | |
| SCHEMBL4101142 | 0.87 | MAP4K4 (0.44) | TLR8MAP4K4TLR7DHFR | |
| SCHEMBL4109882 | 0.87 | TLR8 (0.48) | TLR8NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL4103588 | 0.87 | DHFR (0.41) | HEXAHEXBNPC1TP53RAB9A | |
| SCHEMBL4110201 | 0.86 | HSP90AA1 (0.46) | TLR8NPC1RAB9ASMN1; SMN2DYRK1A | |
| SCHEMBL4102240 | 0.86 | DHFR (0.41) | NPC1TP53RAB9ASMN1; SMN2CHEK2 | |
| SCHEMBL4100948 | 0.84 | CA12 (0.39) | TLR8HEXAHEXBNPC1TP53 | |
| SCHEMBL4115522 | 0.83 | TLR8 (0.38) | TLR8HEXAHEXBNPC1TP53 | |
| SCHEMBL4107576 | 0.82 | TLR7 (0.43) | TLR8HEXAHEXBMAP4K4NPC1 | |
| SCHEMBL4102279 | 0.82 | KMT2A (0.44) | NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338435-B2 | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | claimed |
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | claimed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-8338435-B2 | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | PNPO, PNP, DPYD | TLR8 936/4885HEXA 837/4885HEXB 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.